Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2
- 1 January 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 55 (1), 90-98
- https://doi.org/10.1161/hypertensionaha.109.138420
Abstract
Angiotensin (Ang)-converting enzyme 2 (ACE2) cleaves Ang II to form Ang-(1-7). Here we examined whether soluble human recombinant ACE2 (rACE2) can efficiently lower Ang II and increase Ang-(1-7) and whether rACE2 can prevent hypertension caused by Ang II infusion as a result of systemic versus local mechanisms of ACE2 activity amplification. rACE2 was infused via osmotic minipumps for 3 days in conscious mice or acutely in anesthetized mice. rACE2 caused a dose-dependent increase in serum ACE2 activity but had no effect on kidney or cardiac ACE2 activity. After Ang II infusion (40 pmol/min), rACE2 (1 mg/kg per day) resulted in normalization of systolic blood pressure and plasma Ang II. In acute studies, rACE2 (1 mg/kg) prevented the rapid hypertensive effect of Ang II (0.2 mg/kg), and this was associated with both a decrease in Ang II and an increase in Ang-(1-7) in plasma. Moreover, during infusion of Ang II, the effect of rACE2 on blood pressure was unaffected by a specific Ang-(1-7) receptor blocker, A779 (0.2 mg/kg), and infusing supraphysiologic levels of Ang-(1-7) (0.2 mg/kg) had no effect on blood pressure. We conclude that, during Ang II infusion, rACE2 effectively degrades Ang II and, in the process, normalizes blood pressure. The mechanism of rACE2 action results from an increase in systemic, not tissue, ACE2 activity and the lowering of plasma Ang II rather than the attendant increase in Ang-(1-7). Increasing ACE2 activity may provide a new therapeutic target in states of Ang II overactivity by enhancing its degradation, an approach that differs from the current focus on blocking Ang II formation and action.Keywords
This publication has 35 references indexed in Scilit:
- Transgenic Angiotensin-Converting Enzyme 2 Overexpression in Vessels of SHRSP Rats Reduces Blood Pressure and Improves Endothelial FunctionHypertension, 2008
- Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive AgentsHypertension, 2008
- Angiotensin-Converting Enzyme 2 Overexpression in the Subfornical Organ Prevents the Angiotensin II–Mediated Pressor and Drinking Responses and Is Associated With Angiotensin II Type 1 Receptor DownregulationCirculation Research, 2008
- Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney InjuryThe American Journal of Pathology, 2007
- Altered blood pressure responses and normal cardiac phenotype in ACE2-null miceJCI Insight, 2006
- Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic MiceHypertension, 2004
- Ang II Accumulation in Rat Renal Endosomes During Ang II-Induced HypertensionHypertension, 2002
- Angiotensin-(1-7): a new hormone of the angiotensin system.Hypertension, 1991
- Hypertension and coronary artery disease. Can the chain be broken?Hypertension, 1991
- Actions of angiotensin peptides after partial denervation of the solitary tract nucleus.Hypertension, 1990